Scholarlink

Purpose <p>Prostate cancer is under-researched in many Asian countries because the paucity of comprehensive cancer registries has prevented large studies from comparing primary prostate cancer therapies. We aimed to provide further insights into recent trends in primary prostate cancer management across multiple Asian countries and regions according to universal health coverage.</p> Methods <p>This is part of the Asian Prostate Cancer (A-CaP), a prospective and multicenter study conducted in 12 Asian countries. The study cohort comprised patients newly diagnosed between January 2016 and December 2018. Patients were allocated to three categories according to the universal health coverage effective coverage index (Category 1 ≥ 80; Category 2, 70–79; and Category 3, &lt; 70). We assessed primary management of prostate cancer according to these categories and by clinic pathological characteristics such as clinical stage, and D’Amico risk group.</p> Results <p>In total, 34,994 patients were included in the final analysis. Category 1 had the highest proportion of patients diagnosed at early stages and Category 3 had the highest proportion of patients diagnosed at advanced stages. Most patients in Category 1 had undergone computed tomography scans, magnetic resonance imaging, and bone scans. In contrast, only 1.7% and 5.4% of men in Categories 2 and 3, respectively, had undergone all three of these investigations. The proportion of patients who had undergone radiation and androgen deprivation therapy as primary treatment was highest in Category 1, whereas the rate of conservative management was highest in Category&#xa0;2. More patients in Category 3 than in the other two categories had undergone radical prostatectomy, but fewer had been treated with radiation therapy.</p> Conclusions <p>Our findings highlighted differences in patterns of treatment of newly diagnosed prostate cancer across 12 Asian countries and regions and suggest that, despite guidelines, health access affects treatment received.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Primary management of prostate cancer by universal health coverage effective coverage index

  • 期刊论文

  • 发表日期：

    2025年3月4日

查看全文
  • Leandro Blas,
  • Masaki Shiota,
  • Mizuki Onozawa,
  • Jae Young Joung,
  • Kyo Chul Koo,
  • Levent Türkeri,
  • Bahadır Şahin,
  • Jasmine Lim,
  • Teng Aik Ong,
  • Peter Ka-Fung Chiu,
  • Chi-Fai Ng,
  • Tong-Lin Wu,
  • Vu Le Chuyen,
  • Bannakij Lojanapiwat,
  • Jason L. Letran,
  • Lukman Hakim,
  • Edmund Chiong,
  • Ghazi M. Al-Edwan,
  • Satoru Taguchi,
  • Yoshiyuki Yamamoto,
  • Shinichi Sakamoto,
  • Taketo Kawai,
  • Masatoshi Eto,
  • Tohru Nakagawa,
  • Shiro Hinotsu,
  • Haruki Kume

摘要

Purpose

Prostate cancer is under-researched in many Asian countries because the paucity of comprehensive cancer registries has prevented large studies from comparing primary prostate cancer therapies. We aimed to provide further insights into recent trends in primary prostate cancer management across multiple Asian countries and regions according to universal health coverage.

Methods

This is part of the Asian Prostate Cancer (A-CaP), a prospective and multicenter study conducted in 12 Asian countries. The study cohort comprised patients newly diagnosed between January 2016 and December 2018. Patients were allocated to three categories according to the universal health coverage effective coverage index (Category 1 ≥ 80; Category 2, 70–79; and Category 3, < 70). We assessed primary management of prostate cancer according to these categories and by clinic pathological characteristics such as clinical stage, and D’Amico risk group.

Results

In total, 34,994 patients were included in the final analysis. Category 1 had the highest proportion of patients diagnosed at early stages and Category 3 had the highest proportion of patients diagnosed at advanced stages. Most patients in Category 1 had undergone computed tomography scans, magnetic resonance imaging, and bone scans. In contrast, only 1.7% and 5.4% of men in Categories 2 and 3, respectively, had undergone all three of these investigations. The proportion of patients who had undergone radiation and androgen deprivation therapy as primary treatment was highest in Category 1, whereas the rate of conservative management was highest in Category 2. More patients in Category 3 than in the other two categories had undergone radical prostatectomy, but fewer had been treated with radiation therapy.

Conclusions

Our findings highlighted differences in patterns of treatment of newly diagnosed prostate cancer across 12 Asian countries and regions and suggest that, despite guidelines, health access affects treatment received.